ARCHIVES

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

This article is from The Cancer Letter archive.

Vol. 36 No. 24 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: DeVita, Seffrin Head Committee advising Feinstein On National Cancer Revision

November 5, 1999

NCI Cooperative Group, Cancer Center Trials Listed

September 30, 2005

NCI To Proceed With Guidelines Unless Board Strongly Disagree

May 9, 1980

Immunotherapy Demonstrates Disease Control in Phase II Study

September 28, 2012

DeVita: No Decision Yet On FCRF Award

July 17, 1987

Compromise on 6,000 Grants Would Make NCI Payline Around 163-164: Natcher Committee Close to Markup

June 28, 1985